XOMA to Present at Adams Harkness 25th Annual Summer Seminar
Tuesday July 19, 2:25 pm ET
BERKELEY, Calif.--(BUSINESS WIRE)--July 19, 2005--XOMA Ltd. (Nasdaq:XOMA - News) announced today that David Boyle, XOMA's chief financial officer, and Bob Gundel, vice president of preclinical research, will provide an overview of XOMA's business strategy and update of the Company's current pipeline and ongoing collaborations at the Adams Harkness 25th Annual Summer Seminar in Boston, MA on Thursday, August 4, 2005 at 10:00 a.m., eastern time.
An audio webcast of the presentation will be available live, and can be accessed via a link on the XOMA website at xoma.com. An archived version of the webcast will be available through the XOMA website until August 31, 2005.
About XOMA
XOMA develops for commercialization antibody and other protein-based biopharmaceuticals, with a therapeutic focus on cancer, immune disorders and infectious diseases. XOMA has a royalty interest in RAPTIVA®, a product marketed worldwide that was developed in collaboration with Genentech. The Company pipeline includes proprietary products along with collaborative product development programs. For more information about XOMA's product pipeline and antibody product development capabilities and technologies, please visit XOMA's website at xoma.com. |
